Premium Essay

Valuing Biotech Companies

In: Business and Management

Submitted By almasy99
Words 5247
Pages 21
FORENSIC ACCOUNTING SPECIAL INTEREST GROUP VALUING A BIOTECHNOLOGY COMPANY
DAVID RANDERSON ACUITY TECHNOLOGY MANAGEMENT PTY LTD Melbourne, May 2001

1.

Valuation Methodologies

Techniques used for valuing intangible assets, of which intellectual property (IP) is one form, may be put into three main categories1: 1. Cost Based; 2. Market Based; and 3. Revenue Based. Biotechnology companies, because their main assets are generally IP, have values that are invariably determined by their intangible assets. The valuation of a mature company tends to follow a methodology that draws heavily on its historical income, either by performing a discounted cash flow of future earnings the confidence in which derives from past activity, or capitalisation of maintainable earnings. Another technique considers the orderly realisation of assets. As most biotechnology companies have no historical revenues and the tangible assets are not representative of a company’s real value, these methods are seldom applicable. Conceptually, the value of a company is the sum of its assets value. However, accounting practices allow companies to reflect only the tangible part of their assets. Obviously, high valuations of companies that are in negative cash flow and with minimal tangible assets is causing concern to the taxation office (as demonstrated by their stance on core technology valuations in R&D syndicates) and the Australian Securities and Investment Commission (ASIC).

1

Reilly RF, Schweihs RP, Valuing Intangible Assets, 1998.

Determining the worth of a research project or R&D based company by discounting free cash flow is more often than not of questionable worth since such methods often result in negative value. Biotechnology companies, as well as other high technology companies, trade on stock exchanges with considerable value. In addition, these companies raise capital,…...

Similar Documents

Premium Essay

Valuing Ipos

...Journal of Financial Economics 53 (1999) 409 }437 Valuing IPOs Moonchul Kim , Jay R. Ritter * Department of Accounting, KyungHee University, C1 Hoegie-Dong, Dongdaemun-Ku, Seoul 130-701, South Korea Department of Finance, School of Business Administration, University of Florida, Gainesville, FL 32611-7168, USA Received 3 June 1997; received in revised form 18 August 1998 Abstract The use of accounting information in conjunction with comparable "rm multiples is widely recommended for valuing initial public o!erings (IPOs). We "nd that the price}earnings (P/E), market-to-book, and price-to-sales multiples of comparable "rms have only modest predictive ability without further adjustments. This is largely due to the wide variation of these ratios for young "rms within an industry. P/E multiples using forecasted earnings result in much more accurate valuations than multiples using trailing 1999 Elsevier Science S.A. All rights reserved. earnings. JEL classixcation: G24 Keywords: Initial public o!erings; Valuation; Comparable "rms * Corresponding author. Tel.: #1-352-846-2837; fax: #1-352-392-0301. E-mail addresses: kimc@nms.kyunghee.ac.kr (M. Kim), jritter@dale.cba.u#.edu (J.R. Ritter) This paper is based on Moonchul Kim's University of Illinois Ph.D. dissertation. We would like to thank seminar participants at Boston, Emory, Georgetown, Humboldt (Berlin), and Vanderbilt Universities, the Universities of Miami and Texas, the Stockholm School of Economics, the Chinese......

Words: 13092 - Pages: 53

Premium Essay

Biotech

...Application, REF: "MARUTI SUZUKI" DIRECT RECRUITMENT'S OFFER. Your Resume has been selected from WWW.MONSTER.COM SHINE.COM and Database for our new plant. The Company selected 62 candidates list for Senior Engineer, IT, Administration, Production, marketing and general service Departments, It is our pleasure to inform you that your Resume was selected as one of the 62 candidates shortlisted for the interview. The Company SUZUKI is the best Manufacturing Car Company in India, The Company is recruiting the candidates for our new Plants in Delhi, Bangalore, and Pune and mumbai.Your interview will be held at The Company Corporate office in New Delhi on 21st Of JANUARY 2013 at 11.30 AM, You will be pleased to know That The 62 candidates selected 55 candidates will be giving appointment, Meaning that your Application can progress to final stage. You have to come in our Company corporate office in New Delhi. Your offer letter with Air Ticket will be sent to you by courier before date of interview. The Company can offer you a salary with benefits for this post 62, 000/- to 200, 000/- P.M. + (HRA + D.A + Conveyance and other Company benefits. The designation and Job Location will be fixing by Company HRD. At time of final process. You have to come with original photo-copies of all required documents below. REQUIRED DOCUMENTS BY THE COMPANY HRD. ====================================== 1) Photo-copies of Qualification Documents. 2) Photo-copies of Experience Certificates (If......

Words: 698 - Pages: 3

Premium Essay

Valuing Stocks

...QUESTIONNAIRE ON VALUING STOCKS By: Bahae eddine Boussouf Nadezda Vovk 1) Common stock: a share of ownership in the corporation, which confers rights to any common dividends as well as rights to vote on election of directors, mergers, or other major events. Preferred stock: A class of ownership in a corporation that has a higher claim on the assets and earnings than common stock. Preferred stock generally has a dividend that must be paid out before dividends to common stockholders and the shares usually do not have voting rights. Preferred and common stocks are different in two key aspects. First, preferred stockholders have a greater claim to a company's assets and earnings. This is true during the good times when the company has excess cash and decides to distribute money in the form of dividends to its investors. In these instances when distributions are made, preferred stockholders must be paid before common stockholders. However, this claim is most important when the company must liquidate and pay all creditors and bondholders, common stockholders will not receive any money until after the preferred shareholders are paid out. Second, the dividends of preferred stocks are different from and generally greater than those of common stock. When you buy a preferred stock, you will have an idea of when to expect a dividend because they are paid at regular intervals. This is not necessarily the case for common stock, as the company's board of directors will decide......

Words: 1128 - Pages: 5

Premium Essay

Valuing Stocks

...Valuing Stocks 1. "As owners, what rights and advantages do shareholders obtain" (Cornett, Adair, & Nofsinger, 2014, p. 203)? They are able to participate in the economic growth of publicly traded firms without having to manage business entities directly. They have the right to residual cash flows of corporate profits and often receive some of these cash flows through dividends. In addition, shareholders vote on the members for board of directors and other proposals for the company. Shareholder capital losses are capped in that they can only lose their initial investment. Stocks are very liquid and investors can enjoy this liquidity in both their entrance into the stock market and their exit from it. 2. "Why might the Standard and Poor's 500 Index be a better measure of stock market performance than the Dow Jones Industrial Average" (Cornett, Adair, & Nofsinger, 2014)? The S&P 500 is a broad market index that includes stocks of the 500 largest US firms from ten sectors of the economy. It captures 80% of the overall stock market capitalization and is a good proxy for what is occurring in the overall stock market. 3. "What are the differences between common stock and preferred stock" (Cornett, Adair, & Nofsinger, 2014, p. 203)? Common stock dividends change over time, hopefully increasing in the long-term. Preferred stock pays a constant dividend. Preferred stockholders have higher precedence for payment in the event of firm......

Words: 528 - Pages: 3

Premium Essay

Walmart Valuing

...VALUING WAL-MART-2010 Contents: 1. Background of Wal-Mart stores, Inc. 2. Valuing approach 3.1 Dividend Discount model 3.2 Capital asset pricing model 3.3 The Price/Earning multiple approach 3. Recommendation 1. Background Wal-Mart stores, Inc. Wal-Mart was the world’s largest retailer, operating more than 8,400 stores worldwide. Wal-Mart’s strategy was to provide a broad assortment of quality merchandise and services at ”everyday low prices”. In general merchandise area, Wal-Mart’s competitors included Sears and Target; In terms of specialty retailers, its competitors included Gap and Limited; Department store competitors included Dillard’s and Macy’s; Grocery store competitors included Safeway and Kroger; The major membership-only warehouse competitor was Costco Wholesale. 2. Valuing approach In this case, I will use three different methods, including the capital asset pricing model (CAPM), the dividend discount model, and the price/earnings multiples, to value the War-Mart, Inc. and to determine whether this company was fairly valued. 3.1 Dividend Discount model * Method introduction According to the dividend discount model(DDM), the current stock price of Wal-Mart represents the present value of all expected future dividends, discounted at an investor’s required rate of return. Under this approach, a share is valued by forecasting dividends in perpetuity. Then, P0 = D1/(Ke – g) * Source of...

Words: 817 - Pages: 4

Premium Essay

On Valuing Nature

...Accounting, Auditing & Accountability Journal On Valuing Nature Ruth Hines Article information: To cite this document: Ruth Hines, (1991),"On Valuing Nature", Accounting, Auditing & Accountability Journal, Vol. 4 Iss 3 pp. Permanent link to this document: http://dx.doi.org/10.1108/09513579110144802 Downloaded on: 22 September 2014, At: 09:07 (PT) References: this document contains references to 0 other documents. To copy this document: permissions@emeraldinsight.com The fulltext of this document has been downloaded 1512 times since 2006* Users who downloaded this article also downloaded: Downloaded by UNIVERSITI UTARA MALAYSIA At 09:07 22 September 2014 (PT) Ruth D. Hines, (1989),"Financial Accounting Knowledge, Conceptual Framework Projects and the Social Construction of the Accounting Profession", Accounting, Auditing & Accountability Journal, Vol. 2 Iss 2 pp. Christine Cooper, (1992),"The Non and Nom of Accounting for (M)other Nature", Accounting, Auditing & Accountability Journal, Vol. 5 Iss 3 pp. Christopher Humphrey, Robert W. Scapens, (1996),"Methodological themes: Theories and case studies of organizational accounting practices: limitation or liberation?", Accounting, Auditing & Accountability Journal, Vol. 9 Iss 4 pp. 86-106 Access to this document was granted through an Emerald subscription provided by 394654 [] For Authors If you would like to write for this, or any other Emerald publication, then please use our Emerald for Authors......

Words: 831 - Pages: 4

Free Essay

Biotech

...January 2014 2014 Global Biotech Outlook Differentiated Growth, Advancing Pipelines Should Drive Outperformance; Conf Call at 11am ET Today The biotech sector had a stellar 2013 (NBI: +65%; S&P: +29%) driven by strong demand for the sector’s key products, many positive phase 3 studies and a wave of successful IPOs. Looking to 2014, we think the fundamental backdrop is very similar with 1) beatable revenue growth expectations (2014e: +16% vs. 2012/2013: +12%) including several high-profile drug launches, 2) many pivotal studies set to read out and 3) a stable/favorable regulatory and reimbursement environment. Notably, these factors should continue to make biotech attractive to generalist investors, who played a major role in the 2013 outperformance. Our bias is to stick with large caps as well as mid-caps with approved products; revenue/EPS/cash flow forecasts for 2015 and beyond look broadly beatable, in our view. In contrast, we suspect that “pure pipeline” or tech platform small caps could be more volatile in 2014. We continue to believe that the biotech industry is in the early innings of an innovation cycle with many labelexpansion opportunities and novel agents in phase 2 or 3 trials that are largely unaccounted for in Street models. Hence, we are bullish on the group for 2014. Please join us for a call today at 11am ET to discuss our sector outlook/favorite names (US dial-in: 888-889-1309; OUS: 773-756-0161; Passcode: BIOTECH).  Large-cap biotech: We don’t......

Words: 13041 - Pages: 53

Premium Essay

Valuing Facebook

...as well. The term "social software" refers to a wide range of web-based programs, services and tools. A key part of these new technologies is their collaborative aspects-- social software allows users to contribute create and customize in ways that earlier models of software do not. Social software includes user-created items like blogs, wikis and podcasts; user-enhanced services such as photo-, video- and music-sharing sites; alternative communication resources such as instant messaging and virtual worlds; and social networking sites. History of Facebook Facebook being a social network is a privately owned company headquartered in Palo Alto, California. Mark Zuckerberg, age 24 and a Harvard drop-out, is ranked 785 in Forbes Magazine's list of the world's billionaires, with a net worth of approximately $1.5 billion. The current employees enrolled in the company amounts for more than 10,000, an the key subsidiaries include Instagram, WhatsApp, Oculus VR, PrivateCore. Facebook was created in 2004 by Harvard student Mark Zuckerberg. The website was intended to be an online version of the University's printed Facebook, a directory of new students. At that time, membership to the website was limited to Harvard students only. In a month's time, Facebook grew to include other Ivy League students as well, and within a year had over 1 million users. By the end of 2005, Facebook expanded to include, first, a network of 800 colleges and universities, then high schools, and......

Words: 1993 - Pages: 8

Premium Essay

Biotech

...Examining five of these sectors: Vertically integrated biotechnology company, biotechnology start-up company, Contract Research/Manufacturing Organizations (CRO/CMO), Fuel biotechnology and Agri-biotechnology we can see what the unique properties each of these sectors have and what they share with each other. Vertically Integrated Biotechnology Company Vertical integration is the replacement of transactions in the marketplace with internal transactions within the company. Vertical integration is the result of mergers acquisitions of other companies that once supplied the parent company. It allows the company to control the economy of its products. The use of this business model has led to many advantages and disadvantages within the biotechnology industry. Vertical integration of biotech companies has offered many advantages to the growth of not only the business but also the growth of the technology offered by the company. However, growth through integration can also have many disadvantages. By examining both we can see how vertical integration plays a part in the growth of a biotechnology company. The vertical integration model has been around for many decades. Biotechnology companies apply this business model to grow and strengthen the business of the company. Vertical integration allows companies to control products from raw materials to end product. This type of business model allows the company to better manage the supply chain to ensure the product is......

Words: 1107 - Pages: 5

Premium Essay

Valuing Stocks

...Average set a new high. The index closed at 14,539.14, which was up 83.86 points from the previous day's close of 14.455.28. What was the return (in percent to four decimal places) of the stock market for March 14, 2013" (Cornett, Adair, & Nofsinger, 2014)? "At your brokerage firm, it costs $9.50 per stock trade. How much money do you need to buy 300 shares of Time Warner, Inc. (TWX), which trades at $22.62" (Cornett, Adair, & Nofsinger, 2014)? "Financial analysts forecast Safeco Corporation (SAF) growth for the future to be a constant 10 percent. Safeco's recent dividend was $1.20. What is the value of Safeco stock when the required return is 12 percent" (Cornett, Adair, & Nofsinger, 2014, p. 205)? "A preferred stock from Duquesne Light Company (DQUPRA) pays $2.10 in annual dividends. If the required return on the preferred stock is 5.4 percent, what is the value of the stock" (Cornett, Adair, & Nofsinger, 2014, p. 204)? "Ultra Petroleum (UPL) has earnings per share of $1.56 and a P/E ratio of 32.48. What is the stock price" (Cornett, Adair, & Nofsinger, 2014, p. 205)?...

Words: 261 - Pages: 2

Premium Essay

Valuing Bonds

...Valuing Bonds 1. "What does a call provision [call feature] allow [bond] issuers to do, and why would they do it" (Cornett, Adair, & Nofsinger, 2014)? “A call provision on a bond issue allows the issuer to pay off the bond debt early at a cost of the principal plus any call premium. Most of the time a bond issuer is called, it is because interest rates have substantially declined in the economy. The issuer calls the existing bonds and issues new bonds at the lower interest rate. This reduces the interest payments the issuer must pay each year” (Cornett, Adair, & Nofsinger, 2014). 2. "Provide the definitions of a discount bond and premium bond. Give examples" (Cornett, Adair, & Nofsinger, 2014, p. 178). “A discount bond is simply a bond that is selling below its par value. It would be quoted at a price that is less than 100 percent of par, like 99.05. A premium bond is a bond selling above its par value. Its price will be quoted as over 100 percent of par value, like 101.15. A bond becomes a discount bond when market interest rates rise above the bond’s coupon rate. A bond becomes a premium bond when market interest rates fall below the bond’s coupon rate” (Cornett, Adair, & Nofsinger, 2014, p. 178). 3. "Describe the differences in interest payments and bond prices between a 5 percent coupon bond and a zero coupon bond" (Cornett, Adair, & Nofsinger, 2014, p. 178). “The 5 percent coupon bond pays annual interest...

Words: 565 - Pages: 3

Premium Essay

“Valuing Tangible Non-Current Assets Is Subjective and Complex and Can Therefore Result in Different Companies Valuing Similar Assets Very Differently”

...“Valuing tangible non-current assets is subjective and complex and can therefore result in different companies valuing similar assets very differently” Financial reporting attempts to measure the worth of assets, a concept that is inherently subjective and arbitrary. We can never know the true value of an asset, and rather than being an objective truth, valuations are always biased. Financial reporting is used for different purposes by different users and so each different way might be appropriate in different circumstances and values are affected by the purpose of measurement. Property, plant and equipment are the main non-current assets that a company holds. Similar assets can be valued differently in different companies due to several different factors which I will discuss in this essay. Tangible non-current assets are usually valued by using the historical cost, which is the initial cost of acquiring the asset to the company. The IFRS states that the historical cost of an item not only includes the price paid for it, but also “any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.” This includes transportation and labour costs, and the cost of site preparation. Different companies may have different views on whether costs involved in bringing the asset into use should be counted as part of the asset or an expense, and often small costs that should be......

Words: 1373 - Pages: 6

Premium Essay

Finance Course - Hypothetical Biotech Case

...Table of Contents I. Early/mid stage biotech funding environment at a glance II. “Regenerate Biomedical” (fictional biotech company) overview a. Company milestones, stakeholders, funding to date b. Preliminary testing results for DRX c. Clinical Trials and funding needs for DRX d. Overview of Phase I Results for DRX e. Probability DRX clears phase II III. Market Overview - Hair Therapy Industry a. Market and competitive landscape b. DRX competitive advantage c. DRX Sales Forecast (three scenarios) d. Analyst Assumptions IV. Risk Profile for early/mid stage biotech companies a. Assumptions- Beta, Cost of Capital, WACC V. Overview Regenerate Biomedical funding options for DRX a. Initial Public Offering (IPO) b. Private Equity (PE) c. Big pharmaceutical company a. “Aderans” preliminary acquisition offer d. Venture Capital b. “Bio Venture” preliminary deal terms VI. Results and Conclusion a. Strategy 1 b. Strategy 2 c. Strategy 3 I. Early/mid stage biotech funding environment at a glance Biotechnology is typically defined as any science that harnesses cellular and bimolecular substances to develop new technology, drugs and products. Biotechnology has multiple applications - food alteration, genetic research, environment and energy, and human and animal health products, to name a few. Over the years, the biotech industry has produced some of the world’s greatest advances......

Words: 4652 - Pages: 19

Premium Essay

Biotech

...are provided to illustrate the application of the various views under Issue 2 of Issue Summary No. 1, Supplement No. 1. Fact Pattern - Biotech License and R&D Contract Biotech Company (Biotech) enters into an agreement with Pharmaceutical Company (Pharma) on January 1, 20X1. The agreement includes Biotech (a) licensing certain intellectual property rights to Pharma and (b) providing research and development (R&D) services to Pharma with the objective of developing a viable drug candidate and receiving U.S. Food and Drug Administration (FDA) approval of the drug candidate. Arrangement consideration is as follows: • • Biotech receives $5 million in licensing fees upon signing the agreement Biotech receives $250,000 per year for each full-time equivalent (FTE) that performs R&D activities • Milestone Events: 1. Biotech receives $2 million upon identification of a viable drug candidate 2. Biotech receives $3 million upon successful Phase II clinical trial completion 3. Biotech receives $5 million upon FDA approval. The license and FTE fees are comparable to rates charged by Biotech in other arrangements and are also considered comparable to rates charged by Biotech's competitors and contract research organizations. None of these payments, once received, are refundable, even if FDA approval is never received. In addition, while Biotech must perform on a best-efforts basis, it is not obligated to achieve the milestones. Biotech’s analysis of its other R&D arrangements......

Words: 1563 - Pages: 7

Premium Essay

Accounting in Biotech

...The business and scientific research domains have remained discrete to each other until recent global financial crisis. However, the economic downturn and increasing demand for alternative healthcare products have brought the paradigm shift in past couple of years. Substantial decline in federal research support have pushed scientists to find alternate ways to support their research. Across the globe these financial pressures, evolving scientific technologies and growing demand of healthcare industry turned several biomedical researchers into bioentrepreneurs. According to a latest report the Biotech industry is on track to raise $44 billion in 2011—the most ever, including the genomics bubble of 2000. Biotech indexes performed well and the private biotech sector was also up, raising $2.9 billion (1) (also see appendix: 1). Moreover, according to the recent IMS world review and McKinsey Global Institute Report, USA remains on top with 444 billion USD projected pharmaceutical markets by year 2015 (2). These emerging trends in biotechnology sector prompted several others like me to explore the path of bioentrepreneurship however, after investing my past 15 years as a pure biomedical researcher the language of accounting is as foreign to me as any biotechnological lingo for an accountant. Thus I started to acquaint myself with this new business language. I firmly believe that a journey of biomedical scientist starting from bench side (of a basic research......

Words: 318 - Pages: 2